Maze Therapeutics, Inc. (NASDAQ:MAZE) Stock Has Average Price Target of $63.40

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) have been given a consensus rating of “Buy” by the thirteen analysts that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, nine have given a buy recommendation and three have issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $63.40.

MAZE has been the topic of several research analyst reports. Wall Street Zen cut Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Wedbush reaffirmed an “outperform” rating and issued a $48.00 price objective on shares of Maze Therapeutics in a report on Wednesday, September 23rd. HC Wainwright reiterated a “buy” rating and set a $110.00 price objective on shares of Maze Therapeutics in a research report on Thursday, September 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a report on Monday, September 21st. Finally, TD Cowen raised Maze Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th.

Insider Buying and Selling

In other Maze Therapeutics news, CEO Jason V. Coloma sold 34,501 shares of the stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $27.02, for a total value of $932,217.02. Following the completion of the sale, the chief executive officer owned 15,558 shares in the company, valued at approximately $420,377.16. This represents a 68.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the stock in a transaction dated Tuesday, September 29th. The stock was sold at an average price of $27.06, for a total value of $202,950.00. Following the sale, the insider owned 32,316 shares of the company’s stock, valued at $874,470.96. This represents a 18.84% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 192,991 shares of company stock worth $5,152,084. Company insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On Maze Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MAZE. Squarepoint Ops LLC lifted its position in Maze Therapeutics by 42.8% during the second quarter. Squarepoint Ops LLC now owns 19,434 shares of the company’s stock valued at $580,000 after purchasing an additional 5,822 shares during the last quarter. Frazier Life Sciences Management L.P. raised its position in shares of Maze Therapeutics by 10.2% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock valued at $150,182,000 after buying an additional 465,641 shares in the last quarter. AXQ Capital LP lifted its holdings in shares of Maze Therapeutics by 114.1% in the 2nd quarter. AXQ Capital LP now owns 15,193 shares of the company’s stock valued at $453,000 after acquiring an additional 8,098 shares during the last quarter. Braidwell LP bought a new position in shares of Maze Therapeutics in the 2nd quarter valued at about $34,019,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Maze Therapeutics by 4,054.3% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,739 shares of the company’s stock worth $529,000 after acquiring an additional 17,312 shares in the last quarter.

Maze Therapeutics Stock Down 0.8%

MAZE opened at $26.43 on Thursday. The stock has a market capitalization of $1.47 billion, a price-to-earnings ratio of -10.49 and a beta of 2.16. The firm has a 50 day moving average price of $26.97 and a 200-day moving average price of $28.22. Maze Therapeutics has a twelve month low of $21.95 and a twelve month high of $53.65. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09.

Maze Therapeutics (NASDAQ:MAZE) last issued its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.76). Equities research analysts forecast that Maze Therapeutics will post -2.72 earnings per share for the current year.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetic diseases. The company uses human genetics and its Maze Compass platform to identify disease-causing biological mechanisms and design small-molecule therapies intended to address the underlying drivers of disease.

Maze’s pipeline includes MZE001, an investigational oral therapy designed to inhibit glycogen synthase as a potential treatment for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles.